Dare Bioscience, Inc. 8-K

What Happened
Dare Bioscience, Inc. (DARE) filed an 8‑K (Item 3.02) reporting that it completed closings of its Regulation A offering on May 1, 4, 5 and 6, 2026. The company issued an aggregate 195,010 Investor Units at an offering price of $5.00 per unit (gross proceeds of $975,050). Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two warrants (Investor Warrants), which, in total, are exercisable for up to 390,020 shares of common stock. The offering was conducted under Form 1‑A (File No. 024‑12688), qualified by the SEC on April 1, 2026; related offering materials were dated January 6, 2026, with a supplement dated March 26, 2026.

Key Details

• Issued 195,010 Investor Units (195,010 shares of Series A Convertible Preferred Stock).
• Investor Warrants issued to purchase up to 390,020 shares of common stock (two warrants per Unit).
• Offering price: $5.00 per Investor Unit; aggregate gross proceeds: $975,050.
• Closings occurred May 1, 4, 5 and 6, 2026; offering statement Form 1‑A qualified April 1, 2026; terms previously disclosed in the company’s Jan 29, 2026 Form 8‑K.

Why It Matters
This filing notifies investors that Dare raised nearly $1.0 million through a Regulation A sale and granted warrants that could increase the company’s share count if exercised. The Series A preferred shares and the Investor Warrants may affect future dilution and capitalization; conversion and exercise terms were disclosed in prior offering materials (see the referenced Form 1‑A and the company’s Jan 29, 2026 8‑K). Investors should review those documents for the specific conversion/exercise mechanics and timing to assess potential impact on shares outstanding and ownership percentages.